| Next 10 |
Ad
KURA News and Press Kura Oncology Inc.
-
2023-03-19 04:00:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
-
– Presentations to highlight preclinical data supporting combination of FTIs with KRAS G12C inhibitors and tyrosine kinase inhibitors – SAN DIEGO, March 14, 2023 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to...
-
2023-03-09 12:00:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
-
Summary Syndax Pharmaceuticals, Inc. has two pivotal trials with data readouts coming up in 2023, with possible regulatory filings. They are loaded with cash after a successful offering. Despite current highs, I see further upside in 2023. Syndax Pharmaceuticals, Inc. ( ...
-
SAN DIEGO, March 01, 2023 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that Troy Wilson, Ph.D., J.D., President and Chief Executive Officer,...
-
Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This report optimizes trading in ...
-
Kura Oncology, Inc. (KURA) Q4 2022 Earnings Conference Call February 23, 2023 4:30 PM ET Company Participants Pete De Spain - Senior Vice President of Investor Relations and Corporate Communications Troy Wilson - President and Chief Executive Officer Tom Doyle - Senior...
-
Kura Oncology press release ( NASDAQ: KURA ): Q4 GAAP EPS of -$0.49 beats by $0.08 . $438 million in cash, equivalents and investments provide runway into fourth quarter of 2025 For further details see: Kura Oncology GAAP EPS of -$0.49 beats by $0.08
-
– Phase 1 data for ziftomenib highlighted by 30% CR rate among 20 patients with NPM1-mutant AML treated at recommended Phase 2 dose – – Multiple patients dosed in registration-directed trial of ziftomenib in NPM1-mutant AML – – First combination study of...
-
SAN DIEGO, Feb. 16, 2023 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that it will report fourth quarter and full year 2022 financial result...
Stock Information
Get KURA Alerts
News, Short Squeeze, Breakout and More Instantly...
Ad
